Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy.
作者信息
Dhakal Binod, Abedin Sameem, Fenske Timothy, Chhabra Saurabh, Ledeboer Nathan, Hari Parameswaran, Hamadani Mehdi
机构信息
Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, and.
Department of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI.
出版信息
Blood. 2021 Oct 7;138(14):1278-1281. doi: 10.1182/blood.2021012769.
Abstract
摘要
相似文献
1
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy.
Blood. 2021 Oct 7;138(14):1278-1281. doi: 10.1182/blood.2021012769.
2
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
J Hematol Oncol. 2022 Jun 16;15(1):81. doi: 10.1186/s13045-022-01300-9.
3
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy.
Blood Cancer Discov. 2021 Sep 13;2(6):577-585. doi: 10.1158/2643-3230.BCD-21-0142. eCollection 2021 Nov.
4
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Blood. 2021 Sep 2;138(9):811-814. doi: 10.1182/blood.2021012443.
5
SARS-COV-2 vaccination after stem cell transplantation for scleroderma.
Ann Rheum Dis. 2021 Oct;80(10):1354-1355. doi: 10.1136/annrheumdis-2021-220677. Epub 2021 May 28.
6
SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
Am J Hematol. 2022 Jan 1;97(1):30-42. doi: 10.1002/ajh.26385. Epub 2021 Nov 2.
7
Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
Br J Haematol. 2022 Jan;196(2):360-362. doi: 10.1111/bjh.17818. Epub 2021 Sep 2.
8
Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
Transplant Cell Ther. 2023 Jan;29(1):10-18. doi: 10.1016/j.jtct.2022.10.010. Epub 2022 Oct 21.
9
Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
Front Immunol. 2023 May 3;14:1174289. doi: 10.3389/fimmu.2023.1174289. eCollection 2023.
10
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Transplant Cell Ther. 2021 Sep;27(9):796.e1-796.e7. doi: 10.1016/j.jtct.2021.07.005. Epub 2021 Jul 10.
引用本文的文献
1
Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood-brain barrier permeability.
J Nanobiotechnology. 2025 May 26;23(1):382. doi: 10.1186/s12951-025-03415-w.
2
Mitigating and managing infection risk in adults treated with CAR T-cell therapy.
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):116-125. doi: 10.1182/hematology.2024000535.
3
Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.
Br J Haematol. 2024 Dec;205(6):2206-2218. doi: 10.1111/bjh.19874. Epub 2024 Nov 17.
4
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19.
Semin Hematol. 2024 Oct;61(5):321-332. doi: 10.1053/j.seminhematol.2024.08.002. Epub 2024 Aug 23.
5
COVID-19 and Cancer Care: A Review and Practical Guide to Caring for Cancer Patients in the Era of COVID-19.
Curr Oncol. 2024 Sep 10;31(9):5330-5343. doi: 10.3390/curroncol31090393.
6
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group.
Leukemia. 2024 Sep;38(9):1985-1991. doi: 10.1038/s41375-024-02336-1. Epub 2024 Jul 23.
7
Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies.
Cancer Med. 2024 Jun;13(12):e7372. doi: 10.1002/cam4.7372.
8
Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients.
Int J Hematol. 2024 Aug;120(2):229-240. doi: 10.1007/s12185-024-03802-3. Epub 2024 Jun 6.
9
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
Clin Infect Dis. 2024 Aug 16;79(2):542-554. doi: 10.1093/cid/ciae291.
10
Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes.
Viruses. 2024 Apr 26;16(5):685. doi: 10.3390/v16050685.
本文引用的文献
1
Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.
Am J Transplant. 2021 Aug;21(8):2727-2739. doi: 10.1111/ajt.16701. Epub 2021 Aug 4.
2
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
J Hematol Oncol. 2021 May 17;14(1):81. doi: 10.1186/s13045-021-01090-6.
3
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
4
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.
Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.
5
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
Blood. 2021 Jul 1;137(26):3674-3676. doi: 10.1182/blood.2021011904.
6
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
7
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.
JAMA. 2021 May 4;325(17):1784-1786. doi: 10.1001/jama.2021.4385.
8
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
9
Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation.
J Clin Microbiol. 2021 Mar 19;59(4). doi: 10.1128/JCM.03149-20.
10
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.
Zotero 插件